Ovid Therapeutics
NEWS
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
Ovid Therapeutics Inc. announced that Amit Rakhit, M.D., President and Chief Medical Officer, will participate in an analyst-led fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 4:00 p.m. EST.
Ovid Therapeutics Inc. announced positive initial data from the ENDYMION trial, a Phase 2 open-label extension study of soticlestat in patients with rare developmental and epileptic encephalopathies.
OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
As the chief executive officer of Ovid Therapeutics, Jeremy Levin has a lot on his plate. But, there is one thing always in the forefront of Levin’s mind – the patients his company can serve.
Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
JOBS
IN THE PRESS